Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result

P. L. Lip*, P. Cikatricis, A. Sarmad, E. M. Damato, R. Chavan, A. Mitra, S. Elsherbiny, Yit Yang, B. Mushtaq

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data.MethodsA retrospective analysis was carried out on 66 consecutive treatment-naive RVO patients with MO who received our RandOL treatment regimen. Baseline visual acuity (VA) and central retinal thickness (CRT) were compared with 12-month result.ResultsAt 12 months, 77% had significant VA improvement, 52% had ≥3-line improvement, and 15% were worse. Significant improvements in CRT were observed in 97% (baseline median CRT=531 μm (IQR 435-622) reduced to 245 μm (IQR 221-351, P<0.001) at 12 months); 76% achieved a dry fovea at 1 year. Mean number of total injections required was 5.5 (range 2-11) and 6% required ≥9 injections in 1 year. Although 70% received additional Ozurdex, 82% received ≥1 sessions of laser therapy. The BRVO subgroup achieved better VA and CRT improvement at 1 year, but small numbers limit definitive statistical conclusions.ConclusionsOur real-world results using a combination treatment protocol for RVO-related MO achieved similar desirable anatomical and visual outcomes as with a single-agent therapy with less intravitreal re-treatment rates at first year. Randomised controlled studies are needed to evaluate the role of laser and the ideal timing of combination therapy.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalEye (Basingstoke)
Volume32
Issue number3
DOIs
Publication statusPublished - 3 Nov 2017

Bibliographical note

This work is licensed under a Creative
Commons Attribution-NonCommercialNoDerivs
4.0 International License. The images or other
third party material in this article are included in the
article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not
included under the Creative Commons license, users
will need to obtain permission from the license holder to
reproduce the material. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2018

Fingerprint Dive into the research topics of 'Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result'. Together they form a unique fingerprint.

Cite this